Login to Your Account

Did FDA Panel Crown New HCV Standard of Care?

By Mari Serebrov

Friday, April 29, 2011
The unanimous support of the FDA's Antiviral Drugs Advisory Committee Thursday for telaprevir as a treatment for hepatitis C virus (HCV) genotype 1 is good news for Vertex Pharmaceutical Inc., but it could change the game for HCV clinical trials that are ongoing or just getting started.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription